Therapeutic opportunities in polyglutamine disease

被引：55

作者：

Hughes, RE ^{[1
]}

Olson, JM

机构：

[1] Univ Washington, Dept Genet, Dept Med, Div Med Genet, Seattle, WA 98195 USA

[2] Childrens Hosp & Med Ctr, Pediat Oncol Div, Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98105 USA

来源：

NATURE MEDICINE | 2001年 / 7卷 / 04期

关键词：

D O I：

10.1038/86486

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Polyglutamine diseases comprise a class of familial neurodegenerative disorders caused by expression of proteins containing expanded polyglutamine tracts. Great progress has been made in elucidating the molecular mechanisms contributing to polyglutamine pathology, and in identifying potential drug targets. Although much remains to be learned, these advances provide an opportunity for rational approaches to target-based drug discovery.

引用

页码：419 / 423

页数：5

共 56 条

[1] Inflammation and Alzheimer's disease [J].

Akiyama, H ;

Barger, S ;

Barnum, S ;

Bradt, B ;

Bauer, J ;

Cole, GM ;

Cooper, NR ;

Eikelenboom, P ;

Emmerling, M ;

Fiebich, BL ;

Finch, CE ;

Frautschy, S ;

Griffin, WST ;

Hampel, H ;

Hull, M ;

Landreth, G ;

Lue, LF ;

Mrak, R ;

Mackenzie, IR ;

McGeer, PL ;

O'Banion, MK ;

Pachter, J ;

Pasinetti, G ;

Plata-Salaman, C ;

Rogers, J ;

Rydel, R ;

Shen, Y ;

Streit, W ;

Strohmeyer, R ;

Tooyoma, I ;

Van Muiswinkel, FL ;

Veerhuis, R ;

Walker, D ;

Webster, S ;

Wegrzyniak, B ;

Wenk, G ;

Wyss-Coray, T .

NEUROBIOLOGY OF AGING, 2000, 21 (03) :383-421

[2] Ubiquitin, cellular inclusions and their role in neurodegeneration [J].

Alves-Rodrigues, A ;

Gregori, L ;

Figueiredo-Pereira, ME .

TRENDS IN NEUROSCIENCES, 1998, 21 (12) :516-520

[3] Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin [J].

Boutell, JM ;

Thomas, P ;

Neal, JW ;

Weston, VJ ;

Duce, J ;

Harper, PS ;

Jones, AL .

HUMAN MOLECULAR GENETICS, 1999, 8 (09) :1647-1655

[4] Replicating Huntington's disease phenotype in experimental animals [J].

Brouillet, E ;

Condé, F ;

Beal, MF ;

Hantraye, P .

PROGRESS IN NEUROBIOLOGY, 1999, 59 (05) :427-468

[5] Transcriptional dysregulation in Huntington's disease [J].

Cha, JHJ .

TRENDS IN NEUROSCIENCES, 2000, 23 (09) :387-392

[6] Evidence for proteasome involvement in polyglutamine disease:: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro [J].

Chai, YH ;

Koppenhafer, SL ;

Shoesmith, SJ ;

Perez, MK ;

Paulson, HL .

HUMAN MOLECULAR GENETICS, 1999, 8 (04) :673-682

[7]

Chai YH, 1999, J NEUROSCI, V19, P10338

[8] Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease [J].

Chen, M ;

Ona, VO ;

Li, MW ;

Ferrante, RJ ;

Fink, KB ;

Zhu, S ;

Bian, J ;

Guo, L ;

Farrell, LA ;

Hersch, SM ;

Hobbs, W ;

Vonsattel, JP ;

Cha, JHJ ;

Friedlander, RM .

NATURE MEDICINE, 2000, 6 (07) :797-+

[9] OXIDATIVE STRESS, GLUTAMATE, AND NEURODEGENERATIVE DISORDERS [J].

COYLE, JT ;

PUTTFARCKEN, P .

SCIENCE, 1993, 262 (5134) :689-695

[10] LESION OF STRIATAL NEURONS WITH KAINIC ACID PROVIDES A MODEL FOR HUNTINGTONS-CHOREA [J].

COYLE, JT ;

SCHWARCZ, R .

NATURE, 1976, 263 (5574) :244-246

← 1 2 3 4 5 6 →